BioPharma Credit Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	12.59	5.62	135.05	120.53	94.71
Cash & Short-Term Investments	12.59	5.62	135.05	120.53	94.71
Cash Growth	123.97%	-95.84%	12.05%	27.26%	-51.00%
Accounts Receivable	53.6	31.8	20.32	19.84	10.01
Total Current Assets	66.19	37.42	155.37	140.37	104.72
Long-Term Investments	1,102	1,162	1,201	1,224	1,266
Total Assets	1,168	1,200	1,357	1,364	1,371
Accounts Payable	17.56	17.88	15.87	26.3	6.34
Total Current Liabilities	17.56	17.88	15.87	26.3	6.34
Other Long-Term Liabilities	-	0.06	-	0.26	0.56
Total Long-Term Liabilities	-	0.06	-	0.26	0.56
Total Liabilities	17.56	17.94	15.87	26.56	6.9
Common Stock	13.74	13.74	13.74	13.74	13.74
Additional Paid-in Capital	607.13	607.13	607.13	607.13	607.13
Accumulated Other Comprehensive Income	-4.33	-21.88	-21.79	2.16	-3.76
Retained Earnings	534.33	582.7	741.79	714.43	746.61
Shareholders' Equity	1,151	1,182	1,341	1,337	1,364
Total Liabilities & Equity	1,168	1,200	1,357	1,364	1,371